Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Vaccinex, Inc.
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
April 02, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
March 27, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
February 21, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex, Inc. Announces Reverse Stock Split
February 15, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
February 07, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
December 04, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
October 31, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
October 26, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Announces Pricing of $9.6 Million Public Offering
September 28, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration
September 28, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
September 27, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer
September 26, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex, Inc. Announces Reverse Stock Split
September 22, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET
June 01, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 15, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
April 25, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells
April 12, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Announces Private Placement with Commitments of $5.0 Million
April 03, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs
April 03, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference
March 23, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
March 21, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis
March 09, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology
January 09, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
SURF
VCNX
Vaccinex Announces $3.8 Million Private Placement
November 28, 2022
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update
November 14, 2022
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer
November 10, 2022
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.